Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Minhee Kang, Ph.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
education and training
Harvard University, Cambridge, MAPh.D.Biostatistics
Cornell University, Ithaca, NYM.S.Operations Research
Brown University, Providence, RISc.B.Applied Mathematics
awards and honors
1998 - 2003
Howard Hughes Medical Institute Predoctoral Fellowship in Biological Sciences

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kang M, Kendall MA, Ribaudo H, Tierney C, Zheng L, Smeaton L, Lindsey JC. Incorporating estimands into clinical trial statistical analysis plans. Clinical Trials. 2022; 19(3):285-291.
  2. Kang M, Umbleja T, Ellsworth G, Aberg J, Wilkin T. Effects of Sex, Existing Antibodies, and HIV-1-Related and Other Baseline Factors on Antibody Responses to Quadrivalent HPV Vaccine in Persons With HIV. J Acquir Immune Defic Syndr. 2022 04 01; 89(4):414-422. PMID: 34907980; PMCID: PMC8881300.
    Citations:    Fields:    Translation:HumansCells
  3. Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2021 Dec; 8(12):ofab511. PMID: 34926713; PMCID: PMC8677564.
    Citations:    
  4. Nyirenda M, Ngongondo M, Kang M, Umbleja T, Krown SE, Godfrey C, Samaneka W, Mngqibisa R, Hoagland B, Mwelase N, Caruso S, Martinez-Maza O, Dittmer DP, Borok M, Hosseinipour MC, Campbell TB. Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy. J Acquir Immune Defic Syndr. 2020 08 01; 84(4):422-429. PMID: 32265361; PMCID: PMC7365262.
    Citations: 5     Fields:    Translation:Humans
  5. Kang M, Grund B, Hunsberger S, Glidden D, Volberding P. Interim monitoring in a treatment strategy trial with a composite primary endpoint. Contemp Clin Trials. 2019 11; 86:105846. PMID: 31520741.
    Citations:    Fields:    Translation:Humans
  6. Sherman KE, Rouster SD, Kang M, Umbleja T, Sterling R, Butt AA. PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals. Dig Dis Sci. 2018 11; 63(11):2969-2974. PMID: 30218427; PMCID: PMC6408225.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  7. Cespedes MS, Kang M, Kojic EM, Umbleja T, Godfrey C, Webster-Cyriaque JY, Masih R, Firnhaber C, Grinsztejn B, Saah A, Cu-Uvin S, Aberg JA. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1. Papillomavirus Res. 2018 12; 6:15-21. PMID: 30118852.
    Citations: 6     Fields:    Translation:Humans
  8. Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin JN, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok M, Samaneka W, Moses A, Mngqbisa R, Busakhala N, Martínez-Maza O, Ambinder R, Dittmer DP, Nokta M, Campbell TB. As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis. 2018 07 02; 67(2):251-260. PMID: 29365083; PMCID: PMC6030807.
    Citations: 12     Fields:    Translation:Humans
  9. Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2018 Jun; 5(6):ofy103. PMID: 29977962; PMCID: PMC6016417.
    Citations: 3     
  10. Shive CL, Judge CJ, Clagett B, Kalayjian RC, Osborn M, Sherman KE, Fichtenbaum C, Gandhi RT, Kang M, Popkin DL, Sieg SF, Lederman MM, Rodriguez B, Anthony DD. Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. Vaccine. 2018 01 25; 36(4):453-460. PMID: 29254840; PMCID: PMC5767517.
    Citations: 9     Fields:    Translation:Humans
  11. Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. Liver Int. 2018 06; 38(6):1010-1021. PMID: 29091342; PMCID: PMC5930158.
    Citations: 7     Fields:    Translation:HumansCells
  12. Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA. Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. World J Hepatol. 2017 Feb 08; 9(4):217-223. PMID: 28217259; PMCID: PMC5295161.
    Citations: 2     
  13. Judge CJ, Sandberg JK, Funderburg NT, Sherman KE, Butt AA, Kang M, Landay AL, Lederman MM, Anthony DD. Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy. J Acquir Immune Defic Syndr. 2016 11 01; 73(3):258-262. PMID: 27258231; PMCID: PMC5065372.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  14. Jacobson JM, Bosinger SE, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson CC, Flexner C, Clagett B, Plants J, Read S, Purdue L, Myers L, Boone L, Tebas P, Kumar P, Clifford D, Douek D, Silvestri G, Landay AL, Lederman MM. The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Res Hum Retroviruses. 2016 07; 32(7):636-47. PMID: 26935044; PMCID: PMC4931767.
    Citations: 20     Fields:    Translation:HumansCells
  15. Petersen T, Lee YJ, Osinusi A, Amorosa VK, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, Kottilil S, Peters MG. Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. AIDS Res Hum Retroviruses. 2016 07; 32(7):660-7. PMID: 26974581; PMCID: PMC4931749.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  16. Bedimo R, Kang M, Tebas P, Overton ET, Hollabaugh K, McComsey G, Bhattacharya D, Evans C, Brown TT, Taiwo B. Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients. AIDS Res Hum Retroviruses. 2016 Apr; 32(4):325-8. PMID: 26499270; PMCID: PMC4817562.
    Citations: 2     Fields:    Translation:Humans
  17. Kang M, Hollabaugh K, Pham V, Koletar SL, Wu K, Smurzynski M, Aberg JA. Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort. J Acquir Immune Defic Syndr. 2014 Jun 01; 66(2):172-80. PMID: 24694927; PMCID: PMC4169110.
    Citations: 7     Fields:    Translation:Humans
  18. Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, Saah A, Aberg JA, Cu-Uvin S. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014 Jul 01; 59(1):127-35. PMID: 24723284.
    Citations: 62     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  19. Amorosa VK, Luetkemeyer A, Kang M, Johnson VA, Umbleja T, Haas DW, Yesmin S, Bardin MC, Chung RT, Alston-Smith B, Tebas P, Peters MG. Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. HIV Clin Trials. 2013 Nov-Dec; 14(6):274-83. PMID: 24334180; PMCID: PMC4113390.
    Citations: 4     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  20. Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, Amorosa V, Bhattacharya D, Coughlin K, Wong-Staal F, Glesby MJ. Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis. 2014 Mar 01; 209(5):658-67. PMID: 24041792; PMCID: PMC3923538.
    Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
  21. Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ. In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. Am J Clin Nutr. 2013 Aug; 98(2):423-9. PMID: 23739141; PMCID: PMC3712551.
    Citations: 2     Fields:    Translation:HumansCells
  22. Kang M, Cu-Uvin S. Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy. HIV Med. 2012 Jul; 13(6):372-8. PMID: 22257000.
    Citations: 16     Fields:    Translation:HumansCells
  23. Anthony DD, Umbleja T, Aberg JA, Kang M, Medvik K, Lederman MM, Peters MG, Koziel MJ, Overton ET. Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine. 2011 Apr 27; 29(19):3558-63. PMID: 21397720.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  24. Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL, Yu JY, Aberg JA. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine. 2010 Aug 02; 28(34):5597-604. PMID: 20600512; PMCID: PMC2943846.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  25. Kang M, Nicolay U. Evaluation of operational chronic infection endpoints for HCV vaccine trials. Contemp Clin Trials. 2008 Sep; 29(5):671-8. PMID: 18511350.
    Citations:    Fields:    Translation:Humans
  26. McComsey GA, Kang M, Ross AC, Lebrecht D, Livingston E, Melvin A, Hitti J, Cohn SE, Walker UA. Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin Trials. 2008 Mar-Apr; 9(2):126-36. PMID: 18474497.
    Citations: 21     Fields:    Translation:HumansCells
  27. Melvin AJ, Kang M, Hitti J, Livingston E, Cohn SE, Stocker V, Ross AC, Watts H, McComsey GA. Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy. Antivir Ther. 2008; 13(3):349-55. PMID: 18572747.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  28. Kang M and Chung RT. The role of early viral decline in the treatment of hepatitis C in HIV-1 co-infected persons. Journal of AIDS. 2007; 46(3):371-373.
  29. Aweeka FT, Kang M, Yu JY, Lizak P, Alston B, Chung RT. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Med. 2007 Jul; 8(5):288-94. PMID: 17561874.
    Citations: 4     Fields:    Translation:HumansCells
  30. Blackard JT, Kang M, St Clair JB, Lin W, Kamegaya Y, Sherman KE, Koziel MJ, Peters MG, Andersen J, Chung RT. Viral factors associated with cytokine expression during HCV/HIV co-infection. J Interferon Cytokine Res. 2007 Apr; 27(4):263-9. PMID: 17477814; PMCID: PMC4066618.
    Citations: 4     Fields:    Translation:HumansCells
  31. Blackard JT, Kang M, Sherman KE, Koziel MJ, Peters MG, Chung RT. Effects of HCV treatment on cytokine expression during HCV/HIV coinfection. J Interferon Cytokine Res. 2006 Nov; 26(11):834-8. PMID: 17115902; PMCID: PMC4113398.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  32. Kang M, Lagakos SW. Statistical methods for panel data from a semi-Markov process, with application to HPV. Biostatistics. 2007 Apr; 8(2):252-64. PMID: 16740624.
    Citations: 16     Fields:    Translation:HumansCells
  33. Liddicoat RV, Losina E, Kang M, Freedberg KA, Walensky RP. Refusing HIV testing in an urgent care setting: results from the "Think HIV" program. AIDS Patient Care STDS. 2006 Feb; 20(2):84-92. PMID: 16475889.
    Citations: 30     Fields:    Translation:Humans
  34. Kang M, Lagakos SW. Evaluation of log-rank tests for infrequent observations from a multi-state process, with application to HPV vaccine efficacy. Stat Med. 2004 Dec 15; 23(23):3681-96. PMID: 15534891.
    Citations: 1     Fields:    Translation:HumansCells
  35. Kang M, Lagakos SW. Evaluating the role of human papillomavirus vaccine in cervical cancer prevention. Stat Methods Med Res. 2004 Apr; 13(2):139-55. PMID: 15068258.
    Citations: 3     Fields:    Translation:Humans
  36. McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, Kang M, Mofenson L, Cunningham C, Duliege AM, Sinangil F, Spector SA, Jimenez E, Bryson Y, Burchett S, Frenkel LM, Yogev R, Gigliotti F, Luzuriaga K, Livingston RA. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis. 2001 Nov 15; 184(10):1331-5. PMID: 11679925.
    Citations: 21     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  37. Cunningham CK, Wara DW, Kang M, Fenton T, Hawkins E, McNamara J, Mofenson L, Duliege AM, Francis D, McFarland EJ, Borkowsky W. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis. 2001 Mar 01; 32(5):801-7. PMID: 11229849.
    Citations: 33     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  38. Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, McFarland E, Cunningham C, Duliege AM, Francis D, Bryson Y, Burchett S, Spector SA, Frenkel LM, Starr S, Van Dyke R, Jimenez E. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis. 2000 Mar; 181(3):890-6. PMID: 10720509.
    Citations: 18     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Kang's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (179)
Explore
_
Co-Authors (5)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.